TY - JOUR
T1 - Drug Prescriptions for Children With ADHD in Japan
T2 - A Study Based on Health Insurance Claims Data Between 2005 and 2015
AU - Yoshida, Makiko
AU - Obara, Taku
AU - Kikuchi, Saya
AU - Satoh, Michihiro
AU - Morikawa, Yoshihiko
AU - Ooba, Nobuhiro
AU - Yamaguchi, Hiroaki
AU - Mano, Nariyasu
N1 - Funding Information:
The authors thank the Research Group for Health Administrative Data and the Japan Medical Data Center Co., Ltd. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Ministry of Health, Labour, and Welfare (MHLW) of Japan (H24-iyaku-wakate-011).
Publisher Copyright:
© The Author(s) 2019.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Objective: The aim of this study is to investigate the trend of prescription drugs for children with ADHD in Japan. Method: Using health insurance claims data of 3,672,951 people between January 2005 and December 2015, we investigated the trend of prescription drugs for 7,856 children with ADHD. Results: After approval in 2007, the proportion of prescriptions for methylphenidate-osmotic-controlled release oral delivery system tablets was 31.4% in 2009 (adjusted odds ratio [AOR] = 2.72; 95% confidence interval [CI] = [2.12, 3.51]) and reached a plateau approximately after 2009 (AOR = 0.96; 95% CI = [0.94, 0.98]). The proportion of prescriptions for atomoxetine increased from 6.1% in 2008 to 21.8% in 2014 (AOR = 1.12; 95% CI = [1.13, 1.18]). The proportion of prescriptions for aripiprazole and ramelteon increased (all trend p <.001). Conclusion: Prescriptions of drugs for children with ADHD have changed. We need to monitor the safety of ADHD medications among children with ADHD.
AB - Objective: The aim of this study is to investigate the trend of prescription drugs for children with ADHD in Japan. Method: Using health insurance claims data of 3,672,951 people between January 2005 and December 2015, we investigated the trend of prescription drugs for 7,856 children with ADHD. Results: After approval in 2007, the proportion of prescriptions for methylphenidate-osmotic-controlled release oral delivery system tablets was 31.4% in 2009 (adjusted odds ratio [AOR] = 2.72; 95% confidence interval [CI] = [2.12, 3.51]) and reached a plateau approximately after 2009 (AOR = 0.96; 95% CI = [0.94, 0.98]). The proportion of prescriptions for atomoxetine increased from 6.1% in 2008 to 21.8% in 2014 (AOR = 1.12; 95% CI = [1.13, 1.18]). The proportion of prescriptions for aripiprazole and ramelteon increased (all trend p <.001). Conclusion: Prescriptions of drugs for children with ADHD have changed. We need to monitor the safety of ADHD medications among children with ADHD.
KW - ADHD
KW - children
KW - proportion of prescription
UR - http://www.scopus.com/inward/record.url?scp=85065332393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065332393&partnerID=8YFLogxK
U2 - 10.1177/1087054719843179
DO - 10.1177/1087054719843179
M3 - Article
C2 - 31056996
AN - SCOPUS:85065332393
VL - 24
SP - 175
EP - 191
JO - Journal of Attention Disorders
JF - Journal of Attention Disorders
SN - 1087-0547
IS - 2
ER -